BlackSky Technology enters June with its first analyst downgrade in months arriving just as the stock gives back nearly 10% from last week's highs — a collision of rising short interest, fresh bearish coverage, and options traders who are anything but concerned.
The pivot point this week is a fresh call from Jefferies. The firm downgraded BKSY to Hold on June 1, announcing a $50 price target that sits comfortably above the current $43.91 close — yet the direction of travel is unmistakably more cautious. Jefferies had initiated at Buy in December 2025 with a $23 target. The stock has since more than doubled, and the firm is now stepping off. That kind of 180-degree shift from a bellwether mid-cap growth desk matters: it signals the easy money from the re-rating trade may be spent.
Short sellers have taken note. At 19.3% of the free float, short interest is genuinely elevated, and it has been climbing — up 11.4% over the past week alone. The week's rise reverses a month-long drift lower and marks the sharpest seven-day addition since early May. Yet the borrow market tells a meaningfully different story. Availability is relatively comfortable at 126%, well above the tightest levels of the year seen back in early May when it compressed to below 5%. Cost to borrow has also eased — down 26% over the past month to just 0.60%, near multi-month lows. That combination means new shorts are not fighting a tight lending pool; there is no squeeze pressure in the plumbing right now.
Options positioning is a genuine outlier in this setup. The put/call ratio at 0.36 is running below its 20-day average of 0.37, and well below the 52-week high of 1.13 — meaning the options market is skewed heavily toward calls rather than protection. The PCR has actually been falling as the stock has pulled back from its weekly highs, suggesting a portion of the market remains positioned for further upside, or at minimum is not paying for downside hedges. That divergence — rising short interest paired with bullish options flow — is the central tension in BKSY's setup this week.
The Street's bull-bear debate has been reset by the stock's own performance. The consensus remains buy-leaning, with five buys against one hold, but those targets were mostly set when the stock was trading in the $20s and $40s. HC Wainwright holds at $42 — below where the stock trades today. Canaccord reiterated Buy in February with a $26 target, now also underwater relative to price. The Jefferies downgrade is the first honest reckoning with a stock that has outrun its coverage. On fundamentals, BKSY carries an EV/EBITDA of around 56x on the snapshot data and is still loss-making with a net loss approaching $57 million on estimated revenues of $138 million. The EPS surprise factor score sits in the 94th percentile, which is the bright spot: the company has consistently beaten analyst estimates. But the quality picture remains weak — negative ROA, negative free cash flow, and an F-score of 1 indicate a business still consuming capital at pace.
Insider activity adds a worth-noting layer. In March, the CEO, CFO, and Chief Accounting Officer all sold shares at $24 — roughly half the current price. The combined net sales over the trailing 90 days total around $2.2 million. These were likely scheduled plan disposals rather than opportunistic exits, but the fact that senior management was trimming at prices well below today's levels is a data point that short sellers will reference when constructing their thesis.
Next on the calendar is Q2 earnings on August 7. The last earnings release — Q1 results in May — produced a +28% one-day move, the strongest in the recent history. Prior quarters averaged out to much smaller reactions. With the stock having rallied more than 23% over the past month, borrow conditions still accommodating new shorts, and coverage now mixed for the first time since December, the August print becomes the next meaningful event for positioning to resolve around.
See the live data behind this article on ORTEX.
Open BKSY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
